ClinicalTrials.gg
RecruitingNCT07482072PETTAUUpdated Mar 19, 2026

Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study

An observational study in Alzheimer Dementia (AD) and Diabete Type 2, sponsored by Rigshospitalet, Denmark. Recruiting at 1 site in Denmark. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Rigshospitalet, Denmark · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
60
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Alzheimer Disease with a site in Denmark — 7 open to participants now, 13 under way, 4 of them phase 3. Alzheimer Disease · Denmark.

Planned enrollment
8th of 13
60 · median 100
Started
2026
with 1 other
Observational
13 of 58
3 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
58th of 58
by date
Lead sponsor
4 of 58
Rigshospitalet, Denmark

Among the 58 studies in Alzheimer Disease with a site in Denmark, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2026, is one of 13 observational ones, reaches primary completion later than 5 of the 12 other live ones, and was the 58th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 58 studies in Alzheimer Disease with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Alzheimer Disease with a site in Denmark, or all of them as a file.
02

Study summary

Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier or more severely than others. Many people with Alzheimer's disease also have problems with blood flow and sugar handling in the brain, and these changes may play an important role in disease development. People with type 2 diabetes are at especially high risk of developing Alzheimer's disease and often experience a more severe disease course.

This pilot study aims to improve our understanding of how brain blood flow and sugar use are altered in Alzheimer's disease, and whether these changes differ in people with and without type 2 diabetes. We will study three groups: people with Alzheimer's disease without diabetes, people with Alzheimer's disease and type 2 diabetes, and healthy older individuals. By comparing these groups, we aim to identify early brain changes that may contribute to cognitive decline.

Participants will undergo advanced brain imaging using positron emission tomography (PET) scans. One scan uses a radioactive sugar tracer to measure how the brain takes up and uses glucose. Importantly, a new non-invasive method will also allow us to estimate how efficiently glucose is transported from the blood into the brain. This is a key process that may be impaired in Alzheimer's disease, but has previously required invasive procedures. The new approach avoids arterial cannulation, making the study safer and more comfortable for participants.

A second PET scan will assess brain blood flow and blood vessel function, including how well the vessels can respond to increased demand. Participants will also complete cognitive tests to assess memory and thinking abilities.

Ultimately, this research may contribute to earlier diagnosis, better monitoring of disease progression, and development of new treatment strategies for Alzheimer's disease.

Read the detailed description
  1. Synopsis / Summary

    Design: Comparative imaging study.

    Population: 60 participants:

    Group A: 20 patients with suspected Alzheimer's disease (AD) without type 2 diabetes (T2D)

    Group B: 20 patients with suspected AD + T2D

    Group C: 20 healthy age-matched controls

    Procedures:

    Dynamic [11C]PiB positron emission tomography (PET) after acetazolamide: early phase as perfusion/vascular function marker; late phase as β-amyloid load.

    Dynamic [18F]FDG PET with heart scans and prebolus method: glucose transport and cerebral metabolic rate of glucose (CMRglc).

    Magnetic resonance imaging (MRI) (if not available within 5 years and clinically acceptable): assessment of white matter lesions (Fazekas score) and vascular markers.

    Neuropsychological testing (if not already available clinically).

    Primary endpoint: Volume and overlap of abnormal regions across imaging biomarkers (with diabetes status considered).

    Secondary endpoints: Correlation between cognitive index score and biomarker volumes.

    Timeline: First subject first visit Sep 2025; last subject last visit Dec 2026; end of trial Sep 2027.

  2. Background and Rationale

    Dementia prevalence is rising; Alzheimer's disease and vascular dementia account for the majority of cases, often co-existing ("mixed dementia"). AD is characterized by early β-amyloid deposition and later neurodegeneration, with hypometabolism and perfusion abnormalities in characteristic parietotemporal regions. T2D is associated with cognitive impairment and increased dementia risk, potentially via impaired insulin signaling and altered brain glucose handling.

    A key methodological barrier has been robust, clinically feasible quantification of glucose transport across the blood-brain barrier (BBB). Prior work suggests blood-brain glucose transport is sensitive to AD-related changes and may respond to metabolic interventions. Conventional glucose transport estimation requires arterial cannulation and high temporal resolution. We have developed a non-invasive approach using an image-derived input function with heart scanning and a prebolus strategy (method manuscript in preparation), enabling estimation of CMRglc and glucose transport in the same FDG session.

    For vascular reserve, acetazolamide challenge probes endothelial-mediated vasodilation. We will use early-phase [11C]PiB as a perfusion proxy (validated against FDG/perfusion measures in prior studies).

    Overall aim: Map and compare regional extent and overlap of quantitative imaging biomarkers in suspected AD with and without T2D versus healthy controls.

  3. Hypotheses

    Patients with suspected AD are amyloid-positive on [11C]PiB PET.

    Aside from amyloid load, biomarkers show broadly similar regional patterns within subjects, but differ in affected volume.

    Glucose transport impairment affects a larger cortical volume than glucose metabolism impairment (CMRglc).

    Perfusion during vasodilation shows larger affected volume than glucose metabolism.

    White matter lesion burden co-localizes with affected regions and differs by diabetes status.

  4. Objectives and Endpoints 4.1 Primary objective

    Map neurodegenerative PET biomarkers and vascular MRI markers in suspected AD and compare the volume and overlap of regional involvement across biomarkers (accounting for T2D).

    4.2 Secondary objectives

    Relate imaging biomarker volumes to cognitive performance.

    4.3 Primary endpoint

    Volume and overlap of:

    Reduced glucose transport from FDG PET

    Reduced CMRglc from FDG PET

    Increased amyloid load from late [11C]PiB PET (standard uptake value ratio, (SUVR) > 1.5, cortex vs cerebellum)

    Reduced perfusion during vasodilation from early [11C]PiB PET

    White matter lesions (none / some / confluent; incl. Fazekas scoring)

    4.4 Secondary endpoints

    Association between cognitive index score and volumes of the above abnormalities.

    4.5 Exploratory endpoints

    Associations between imaging volumes and metabolic/clinical measures (body mass index (BMI), waist, fasting glucose/insulin measures, etc.).

  5. Methods 5.1 Design

    Comparative cross-sectional imaging study with prespecified group comparisons (A vs B vs C).

    5.2 Schedule

    Procedures are conducted over 2-3 study visits.

  6. Trial Population 6.1 Recruitment

    Patients (A, B): Identified through the memory clinic at Herlev or referrals to clinical brain FDG PET. A health professional asks permission for research contact; written information is provided. Research staff contacts the patient ≥3 days later to screen and offer an information meeting.

    Controls (C): Recruitment via approved advertisements (TrialTree, forskningnu.dk, local media, posters, social media) with safeguards against tagging/comment disclosure.

    6.2 Inclusion criteria

    Written informed consent before any study procedures

    Age 60-90 years

    Group A/B: clinically suspected AD

    Group B: documented T2D

    Group C: no significant somatic/psychiatric disease

    Ability and willingness to comply with protocol

    6.3 Exclusion criteria

    Suspicion of non-AD dementia

    Significant brain disease unrelated to dementia

    Medication affecting perfusion or glucose metabolism (e.g., GLP-1 receptor agonists; metformin/insulin allowed in Group B)

    Active cancer treatment

    Alcohol/drug abuse history

    Severe claustrophobia

    Pregnancy/breastfeeding

    MRI contraindications (metal fragments, pacemaker, incompatible implants, etc.)

    For controls: significant cardiovascular disease or diabetes (atrial fibrillation acceptable)

    6.4 Informed consent

    Consent is voluntary; withdrawal is allowed anytime without consequences for clinical care. Participants are offered up to 7 days to consider participation and may bring a relative/friend to the information meeting. After trial completion, participants will be informed of overall results; individual results will be handled with respect for the right not to know. Permission may be requested for future contact regarding follow-up trials.

    6.5 Demography and clinical data

    DOB, sex, height/weight/BMI, waist, blood pressure/pulse, smoking/alcohol history, medication list, diabetes history (if applicable), relevant clinical cognitive test results.

    6.7 Biobank

    No research biobank is created.

  7. Study Procedures 7.1 [18F]FDG PET

    Visit \~2 hours; replaces routine clinical FDG PET where applicable. 4-hour fasting. Venous access for tracer injection. Dynamic brain scan (\~55 min) with heart scans before and after for non-invasive input function. Total injected activity \~200 MBq split (prebolus + bolus). Plasma glucose measured if needed.

    7.2 [11C]PiB PET + acetazolamide

    Visit \~2 hours. Venous access. Acetazolamide 1 g in 50 mL saline infused over 5 min. After \~10 min, dynamic brain [11C]PiB PET (\~60 min), activity 100-500 MBq.

    7.3 MRI (if needed)

    If brain MRI is \<5 years old and clinically acceptable with no suspected major change, MRI is not repeated. Otherwise \~20 min MRI including sequences relevant for vascular markers and white matter lesions. No contrast.

    7.4 Neuropsychological testing

    Up to 60 min in quiet setting; attention, memory, learning, language, processing speed tests.

  8. Safety, Risks, and Discomfort

    Long dynamic PET sessions may be tiring; staff monitor participants throughout. Adverse events from FDG, PiB and MRI are rare and typically mild. Acetazolamide may cause headache, tingling, increased diuresis, or altered taste of carbonated drinks; serious events are very rare.

    Radiation: FDG (\~4.8 mSv), PiB (\~3.4 mSv), CT (\~3 mSv), total \~11.2 mSv (approx. \<3 years background radiation in Denmark). Many patients would otherwise have routine FDG PET clinically. Only participants ≥60 years are included.

    Incidental findings: Scans are not intended as diagnostic exams. If potentially clinically significant incidental findings are suspected, a radiologist will be consulted; participant and GP will be informed where relevant. Participants who do not wish to be informed of incidental findings with potential health implications will not be scanned.

  9. Data Handling / GDPR

    Data stored for 15 years; thereafter transferred to "Privacy" in anonymised form. Data stored coded in accordance with GDPR and Danish Data Protection rules and registered with the Danish Data Protection Agency. Paper documents destroyed after completion of processing (planned by Dec 2027).

    Access to medical records occurs only after signed consent and is used for eligibility assessment, safety, and analysis variables (diagnoses, medication, relevant labs, prior imaging, cognitive tests). Monitoring authorities may access data under confidentiality obligations.

  10. Statistical Plan 10.1 General

Descriptive statistics including missingness and reasons. Analyses are non-blinded. Deviations from analysis plan will be documented in publications.

10.2 Image analyses (key outcomes)

[11C]PiB early phase: first 10 min reconstructed as "vascular/perfusion" image; outcome = regional uptake relative to cerebellar grey matter; z-scores vs controls.

[11C]PiB late phase: 40-60 min reconstructed for amyloid SUVr; cortical volume with SUVr > 1.5 recorded.

[18F]FDG heart IDIF: VOI in LV cavity; prebolus/bolus ratio applied; late point from last heart scan; plasma conversion via population-based ratio.

[18F]FDG brain: dynamic modelling (two-compartment); lumped constant 0.76; plasma glucose included. Outcomes: CMRglc and K1-based glucose transport estimate.

MRI: neuroradiologist rates Fazekas score, regional white matter lesions, and other vascular findings.

10.3 Sample size

Exploratory. n=20 per group) accounts for \~10% drop-out, expected \~15% differences in affected volumes, power 90%, alpha 5%, and \~14% variation. Participants unable to complete study visits may be replaced.

11. End of Trial / Discontinuation

Ethics Committee informed within 90 days after completion. Participants may discontinue at any time; discontinuation does not affect clinical care.

12. Administrative Procedures

Insurance: Covered under Danish patient insurance law. Finances/COI: Investigator-initiated; no investigators have financial stake. Operating expenses covered by involved departments.

13. Publication

Data owned by Region Hovedstaden. Results will be published regardless of outcome in peer-reviewed journals, following Vancouver authorship guidelines.

03

Conditions studied

  • Alzheimer Dementia (AD)
  • Diabete Type 2

Keywords

  • neuroimaging
  • Alzheimer's disease
  • amyloid
  • glucose transport
  • glucose metabolism
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients are recruited from the memory clinica at Herlev Hospital, Copenhagen, Denmark

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • suspected Alzheimer's disease
  • type 2 diabetes (group A)
  • able and willing to comply with study protocoil´´l

Exclusion criteria

Exclusion Criteria:

  • type 2 diabetes (group B and C)
  • significant brain disease apart from dementia (group A and B)
  • significant vascular or neurological disease (group C)
  • active cancer treatment
  • history of alcohol or drug abuse
  • severe claustrophobia
  • pregnancy or breastfeeding
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alzheimer's disease with type 2 diabetes

    Suspected Alzheimer's disease combined with type 2 diabetes

    Diagnostic Test: [18F]FDG PET · Diagnostic Test: [11C]PIB

  • Alzheimer's disease without type 2 diabetes

    Suspected Alzheimer's disease. No diagnosis of type 2 diabetes

    Diagnostic Test: [18F]FDG PET · Diagnostic Test: [11C]PIB

  • Healthy subjects

    Age-matched subjects with no major vascular or neuroological diseses

    Diagnostic Test: [18F]FDG PET · Diagnostic Test: [11C]PIB

Interventions

  • Diagnostic test[18F]FDG PET

    Regional glucose metabolism as well as glucose transport will be assessed.

  • Diagnostic test[11C]PIB

    Early perfusion PET after acetazolamide infusion as well as late amyloid load will be assessed.

06

What researchers measure

Primary outcomes

  1. Glucose transport

    Regional flux of glucose to brain regions, (mmol/mL/min )

    Time frame: at inclusion

Secondary outcomes

  1. Glucose metabolism

    Regional glucose metabolism, (μmol 100 g-1 min-1)

    Time frame: at inclusion

  2. Amyloid load

    Regional SUVR of amyloid

    Time frame: at inclusion

  3. Stress perfusion

    Perfusion relative to cerebellum during acetazolamide vasodilation. SUVR

    Time frame: at inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gejl M, Brock B, Egefjord L, Vang K, Rungby J, Gjedde A. Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment. Sci Rep. 2017 Dec 13;7(1):17490. doi: 10.1038/s41598-017-17718-y. PubMed 29235507 ↗
  • Bach MJ, Larsen ME, Kellberg AO, Henriksen AC, Fuglsang S, Rasmussen IL, Lonsdale MN, Lubberink M, Marner L. Non-invasive [15O]H2O PET measurements of cerebral perfusion and cerebrovascular reactivity using an additional heart scan. J Cereb Blood Flow Metab. 2025 Jun;45(6):1144-1152. doi: 10.1177/0271678X251313743. Epub 2025 Jan 20. PubMed 39829334 ↗

Individual participant data

Plan to share: Undecided — GDPR regulations

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 19, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07482072
Collaborators
Copenhagen University Hospital at Herlev
Responsible party
Lisbeth Marner (Professor, Copenhagen University Hospital at Herlev) — Principal investigator
First posted
Mar 19, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Lisbeth Marner, MD, DMSc, PhD
Contact
Lisbeth.marner@regionh.dk
+4538682041

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion